Chronic obstructive pulmonary disease in China: a nationwide prevalence study

Liwen Fang, Pei Gao, Heling Bao, Xun Tang, Baohua Wang, Yajing Feng, Shu Cong, Juan Juan, Jing Fan, Ke Lu, Ning Wang, Yonghua Hu, Linhong Wang, Liwen Fang, Pei Gao, Heling Bao, Xun Tang, Baohua Wang, Yajing Feng, Shu Cong, Juan Juan, Jing Fan, Ke Lu, Ning Wang, Yonghua Hu, Linhong Wang

Abstract

Background: Because of the rapid change in economic development and lifestyle in China, and the ageing population, concerns have grown that chronic obstructive pulmonary disease (COPD) could become epidemic. An up-to-date nationwide estimation of COPD prevalence in China is needed.

Methods: We did a cross-sectional survey of a nationally representative sample of individuals from mainland China aged 40 years or older. The primary outcome was COPD, defined according to the 2017 Global Initiative for Chronic Obstructive Lung Disease (GOLD) lung function criteria.

Findings: Between Dec 29, 2014, and Dec 31, 2015, 66 752 adults were recruited to the study population. The estimated standardised prevalence of COPD was 13·6% (95% CI 12·0-15·2). The prevalence of COPD differed significantly between men and women (19·0%, 95% CI 16·9-21·2 vs 8·1%, 6·8-9·3; p<0·0001), mainly because of a significant difference in smoking status between men and women (current smokers 58·2% vs 4·0%). The prevalence of COPD differed by geographic region, with the highest prevalence in southwest China (20·2%, 95% CI 14·7-25·8) and the lowest in central China (10·2%, 8·2-12·2). Among adults with COPD, 56·4% (95% CI 53·7-59·2) had mild disease (GOLD stage I), 36·3% (34·3-38·3) had moderate disease (GOLD stage II), 6·5% (5·5-7·4) had severe disease (GOLD stage III), and 0·9% (0·6-1·1) had very severe disease (GOLD stage IV).

Interpretation: In a large, nationally representative sample of adults aged 40 years or older, the estimated overall prevalence of COPD in China in 2014-15 was 13·6%, indicating that this disease has become a major public-health problem. Strategies aimed at prevention and treatment of COPD are needed urgently.

Funding: Chinese Central Government, the Ministry of Science and Technology of The People's Republic of China, and the National Natural Science Foundation of China.

Copyright © 2018 Elsevier Ltd. All rights reserved.

Figures

Figure
Figure
Prevalence of COPD in the general Chinese population aged 40 years or older (A) Crude and weighted prevalence of COPD, overall and in men and women. (B) Age-specific prevalence of COPD in men and women. Bars represent the prevalance and error bars the 95% CI. Data are presented in the appendix (p 17). COPD=chronic obstructive pulmonary disease.

References

    1. Global Initiative for Chronic Obstructive Lung Disease (GOLD) Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (2017 report) (accessed March 19, 2018).
    1. Adeloye D, Chua S, Lee C. Global and regional estimates of COPD prevalence: systematic review and meta-analysis. J Glob Health. 2015;5:020415.
    1. Dwyer-Lindgren L, Bertozzi-Villa A, Stubbs RW. Trends and patterns of differences in chronic respiratory disease mortality among US counties, 1980–2014. JAMA. 2017;318:1136–1149.
    1. Bousquet J, Khaltaev NG, Cruz AA. Global surveillance, prevention and control of chronic respiratory diseases: a comprehensive approach. 2007. (accessed March 5, 2018).
    1. GBD 2016 Causes of Death Collaborators Global, regional, and national age-sex specific mortality for 264 causes of death, 1980–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390:1151–1210.
    1. World Health Organization Chronic respiratory diseases: burden of COPD. (accessed March 5, 2018).
    1. Zhong N, Wang C, Yao W. Prevalence of chronic obstructive pulmonary disease in China: a large, population-based survey. Am J Respir Crit Care Med. 2007;176:753–760.
    1. Bao H, Fang L, Wang L. Prevalence of chronic obstructive pulmonary disease among community population aged ≥40 in China: a meta-analysis on studies published between 1990 and 2014. Zhonghua Liu Xing Bing Xue Za Zhi. 2016;37:119–124. (in Chinese).
    1. Qiu J, Zhang YN, Chen J. Prevalence of chronic obstructive pulmonary disease in Ningxia Hui Autonomous Region of China. Zhonghua Jie He He Hu Xi Za Zhi. 2013;36:265–268. (in Chinese).
    1. Smith M, Li L, Augustyn M. Prevalence and correlates of airflow obstruction in approximately 317 000 never-smokers in China. Eur Respir J. 2014;44:66–77.
    1. Wang YC, Lin JM, Li CY, Lee LT, Guo YL, Sung FC. Prevalence and risks of chronic airway obstruction: a population cohort study in Taiwan. Chest. 2007;131:705–710.
    1. Kurmi OP, Li L, Smith M. Regional variations in the prevalence and misdiagnosis of air flow obstruction in China: baseline results from a prospective cohort of the China Kadoorie Biobank (CKB) BMJ Open Respir Res. 2014;1:e000025.
    1. Liu S, Wu X, Lopez AD. An integrated national mortality surveillance system for death registration and mortality surveillance, China. Bull World Health Organ. 2016;94:46–57.
    1. Wang L, Gao P, Zhang M. Prevalence and ethnic pattern of diabetes and prediabetes in China in 2013. JAMA. 2017;317:2515–2523.
    1. American Association for Public Opinion Research (AAPOR) Standard definitions: final dispositions of case codes and outcome rates for surveys. 2016. (accessed March 5, 2018).
    1. American Thoracic Society Standardization of spirometry, 1994 update. Am J Respir Crit Care Med. 1995;152:1107–1136.
    1. Buist AS, McBurnie MA, Vollmer WM. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. Lancet. 2007;370:741–750.
    1. Menezes AMB, Perez-Padilla R, Jardim JRB. Chronic obstructive pulmonary disease in five Latin American cities (the PLATINO study): a prevalence study. Lancet. 2005;366:1875–1881.
    1. Jian W, Gao Y, Hao C. Reference values for spirometry in Chinese aged 4–80 years. J Thorac Dis. 2017;9:4538–4549.
    1. Benjamin D, Berger J, Johannesson M. Redefine statistical significance. Nat Hum Behav. 2018;2:6–10.
    1. von Elm E, Altman DG, Egger M. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet. 2007;370:1453–1457.
    1. Srivastava K, Thakur D, Sharma S, Punekar YS. Systematic review of economic burden in symptomatic chronic obstructive pulmonary disease (COPD) patients. Value Health. 2014;17:A173–A174. (abstr PRS26).
    1. Ko FWS, Wong GWK. Drug treatment for early-stage COPD. N Engl J Med. 2017;377:988–989.
    1. Tilert T, Dillon C, Paulose-Ram R, Hnizdo E, Doney B. Estimating the US prevalence of chronic obstructive pulmonary disease using pre- and post-bronchodilator spirometry: the National Health and Nutrition Examination Survey (NHANES) 2007–2010. Respir Res. 2013;14:103.
    1. Fukahori S, Matsuse H, Takamura N. Prevalence of chronic obstructive pulmonary diseases in general clinics in terms of FEV1/FVC. Int J Clin Pract. 2009;63:269–274.
    1. Hong JY, Jung JY, Lee MG. Changes in the prevalence of COPD in Korea between 2001 and 2011 in the KNHANES data. Respir Med. 2017;125:12–18.
    1. Yin P, Jiang CQ, Cheng KK. Passive smoking exposure and risk of COPD among adults in China: the Guangzhou Biobank Cohort Study. Lancet. 2007;370:751–757.
    1. US Preventive Services Task Force (USPSTF) Screening for chronic obstructive pulmonary disease: US Preventive Services Task Force recommendation statement. JAMA. 2016;315:1372–1377.
    1. Press VG, Cifu AS, White SR. Screening for chronic obstructive pulmonary disease. JAMA. 2017;318:1702–1703.
    1. Zhou Y, Zhong NS, Li X. Tiotropium in early-stage chronic obstructive pulmonary disease. N Engl J Med. 2017;377:923–935.
    1. Tian J, Zhou Y, Cui J. Peak expiratory flow as a screening tool to detect airflow obstruction in a primary health care setting. Int J Tuberc Lung Dis. 2012;16:674–680.
    1. Guan W-J, Ran P-X, Zhong N-S. Prevention and management of COPD in China: successes and major challenges. Lancet Respir Med. 2016;4:428–430.
    1. Zhou Y, Hu G, Wang D. Community based integrated intervention for prevention and management of chronic obstructive pulmonary disease (COPD) in Guangdong, China: cluster randomised controlled trial. BMJ. 2010;341:c6387.
    1. Postma DS, Rabe KF. The asthma-COPD overlap syndrome. N Engl J Med. 2015;373:1241–1249.

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa